Abstract
Objectives: This is a longitudinal prospective study which was designed to assess the trend of anti-SARS-CoV-2 antibodies targeting the Spike (anti-S) and Nucleocapside protein (anti-N) viral antigens over a 9-month period after the administration of an anti-SARS-CoV-2 vaccine in a big COVID-19 hospital located in Northern Italy. Participants: 7411 vaccinated workers were included in a linear mixed-effect model analysis performed to model the anti-S decay over the 9 months following the vaccination, during serological screening performed approximately 2, 4, and 9 months following the first jab administration. Serological tests performed in the 9 months preceding vaccine administration were retrospectively analysed to identify the burden of infections occurring before vaccination. Results: The serological assays were used for monitoring the antibody titres during the observational period. Vaccination significantly reduced the rate of infection and elicited a specific humoral response, which lasted during the whole observational period (9 months). A decay was observed in all considered subgroups. At 35 weeks, workers with no history of pre-vaccine infection showed a significantly lower anti-S titre (−2522 U/mL on average (−2589.7 to −2445.7)); younger workers showed significantly higher anti-S titres (140.2 U/mL on average (82.4 to 201.3)). Only seven immunocompromised workers did not show significant levels of anti-S antibodies; three of them, all females, showed a specific T-cell response. Conclusions: Comparing the 9-month periods before and after the first vaccine dose, a significant reduction in infection rate was observed (1708 cases vs. 156). Pre-vaccine infection, especially if contracted during the first pandemic wave, greatly enhanced the response to vaccination, which was significantly affected also by age both in extent and duration (inversely related). A gender effect on the T-cell immune response was observed in a small group of workers who did not produce antibodies after vaccine administration.
Subject
Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology
Reference25 articles.
1. BNT162b2 mRNA COVID-19 Vaccine: First Approval;Lamb;Drugs,2021
2. Chen, X., Huang, H., and Ju, J. (2022). Impact of vaccination on the COVID-19 pandemic in US states. Sci. Rep., 12.
3. Harrison, S., Walters, B., Simmons, Z., Cook, M., and Clark, R. (2022, May 11). The Effectiveness of Vaccination against Long COVID A Rapid Evidence Briefing. UK Health Security Agency. February 2022. Available online: https://ukhsalibrary.koha-ptfs.co.uk/covid19rapidreviews/.
4. Serological surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health workers;Harris;J. Infect.,2021
5. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: A large, multicentre, prospective cohort study (SIREN) [published correction appears in Lancet. 8 May 2021, 397,1710];Hall;Lancet,2021